Mechanism of action
Fexofenadine is a selective antagonist of peripheral histamine H1 receptors. It competitively inhibits histamine binding to H1 receptors on vascular endothelium, smooth muscle, and sensory nerve endings, thereby blocking the inflammatory cascade triggered by allergen exposure.
Key mechanistic features:
- High H1 selectivity: Minimal affinity for muscarinic, alpha-adrenergic, or dopaminergic receptors, resulting in negligible anticholinergic or sedative effects
- Poor CNS penetration: As a zwitterion at physiological pH with low lipid solubility, fexofenadine does not cross the blood-brain barrier in clinically significant amounts
- P-glycoprotein substrate: Actively effluxed from the CNS by P-glycoprotein transporters, further ensuring lack of central effects
- No cardiac effects: Unlike terfenadine (its parent compound), fexofenadine does not block cardiac potassium channels (hERG) and does not prolong QT interval
The drug reduces histamine-mediated symptoms including pruritus, rhinorrhea, sneezing, nasal congestion, and wheal-and-flare skin reactions. Onset of action occurs within 1-2 hours, with peak effect at 2-3 hours and duration of 12-24 hours.
- Fexofenadine is the active carboxylate metabolite of terfenadine, lacking cardiotoxicity and QT prolongation
- Does not undergo CYP450 metabolism—no drug interactions with azole antifungals or macrolide antibiotics
- Fruit juices (orange, grapefruit, apple) reduce absorption by 40-70% via OATP inhibition—space by 2 hours
- Antacids containing aluminum or magnesium reduce bioavailability by 40%—separate dosing by 2 hours
- Minimal CNS penetration (zwitterion, P-glycoprotein substrate)—sedation rate similar to placebo at 1-3%
- Requires dose reduction in renal impairment (CrCl <80 mL/min) as 10% excreted unchanged in urine, 80% in feces
- No anticholinergic effects due to high H1 selectivity—safe in elderly and patients with glaucoma or BPH
- Does not prolong QT interval even at supratherapeutic doses—safe in cardiovascular disease
Indications
Fexofenadine is approved for the symptomatic treatment of allergic conditions where histamine H1 antagonism provides benefit.
Primary indications:
- Seasonal allergic rhinitis (hay fever): Relief of sneezing, rhinorrhea, nasal pruritus, ocular pruritus and tearing in adults and children ≥2 years
- Perennial allergic rhinitis: Year-round symptoms from indoor allergens (dust mites, pet dander, mold) in adults and children ≥6 months
- Chronic idiopathic urticaria: Reduction of pruritus and number/size of hives in adults and children ≥6 months
Off-label uses:
- Symptomatic dermographism
- Adjunct in chronic spontaneous urticaria refractory to standard antihistamine doses
- Physical urticarias (cold, cholinergic, solar)
Fexofenadine does not treat underlying allergic disease and is not indicated for acute anaphylaxis or asthma. It provides symptomatic relief only and should be part of comprehensive allergen avoidance strategies when appropriate.
Pharmacokinetics
Fexofenadine exhibits linear pharmacokinetics with minimal interindividual variability.
Absorption
- Bioavailability: Approximately 30-40% after oral administration
- Time to peak concentration (Tmax): 1-3 hours
- Food effects: Fruit juices (orange, grapefruit, apple) containing organic anion transporting polypeptides (OATP) inhibitors reduce absorption by up to 60%; administration with high-fat meals may decrease bioavailability
Distribution
- Volume of distribution: 5.4-5.8 L/kg
- Protein binding: 60-70%, primarily to albumin
- CNS penetration: Negligible (<1% of plasma concentration in CSF)
Metabolism
- Hepatic metabolism: Minimal; only 5% undergoes metabolism
- Active metabolites: None
- CYP450 involvement: Not a substrate, inducer, or inhibitor of cytochrome P450 enzymes—this is a critical distinguishing feature from terfenadine and reduces drug interaction potential
Elimination
- Routes: Primarily fecal (80%) and urinary (10%) excretion as unchanged drug
- Half-life: 11-15 hours (allows once or twice daily dosing)
- Renal impairment: Half-life increases to 15-20 hours; dose adjustment recommended
- Hepatic impairment: Minimal effect on pharmacokinetics since metabolism is not significant
Fexofenadine is a substrate for P-glycoprotein and organic anion transporting polypeptides, making it susceptible to transporter-mediated drug interactions rather than metabolic interactions.
Adverse effects
Fexofenadine is generally well-tolerated with an adverse effect profile similar to placebo in clinical trials. Most side effects are mild and transient.
Common adverse effects (1-10%):
- Headache (most frequent, 5-10%)
- Drowsiness (1-3%, significantly less than first-generation antihistamines)
- Dizziness (1-2%)
- Nausea and dyspepsia (1-3%)
- Fatigue (1-2%)
- Dysmenorrhea (reported in clinical trials)
Rare adverse effects (<1%):
- Hypersensitivity reactions: urticaria, angioedema, pruritus, rash, anaphylaxis (extremely rare)
- Insomnia or sleep disturbances
- Nervousness or anxiety
- Tachycardia or palpitations
Cardiac safety:
Unlike terfenadine and astemizole, fexofenadine does not prolong QT interval at therapeutic or supratherapeutic doses and is not associated with torsades de pointes. This critical safety advantage led to the withdrawal of terfenadine from the market.
Pediatric considerations:
The adverse effect profile in children is similar to adults. Sedation rates remain low across all age groups.
Comparative sedation:
Fexofenadine produces sedation rates of 1-3%, comparable to placebo and significantly lower than first-generation antihistamines (diphenhydramine 30-70%) and some second-generation agents (cetirizine 10-15%). This makes it appropriate for patients requiring daytime alertness.
Contraindications and warnings
Absolute contraindications:
- Hypersensitivity to fexofenadine or any component of the formulation
- Known hypersensitivity to terfenadine (theoretical cross-reactivity)
Warnings and precautions:
- Renal impairment: Dose reduction recommended for creatinine clearance <80 mL/min due to prolonged half-life and increased AUC
- Pregnancy: FDA Category C (now Pregnancy Category system replaced by PPRN). Animal studies show no teratogenicity; human data limited. Use only if benefit outweighs risk. Second-generation antihistamines are generally preferred over first-generation agents during pregnancy.
- Lactation: Excreted in breast milk in small amounts. The American Academy of Pediatrics considers antihistamines usually compatible with breastfeeding, but monitor infant for drowsiness or irritability.
- Pediatric use: Safety and efficacy established for allergic rhinitis in children ≥6 months and chronic urticaria in children ≥6 months
- Geriatric use: No dose adjustment typically needed, but monitor for increased sensitivity
Special populations:
- Hepatic impairment: No dose adjustment required since fexofenadine undergoes minimal hepatic metabolism
- Cardiovascular disease: Generally safe; no QT prolongation or arrhythmogenic potential
Fruit juice warning:
Patients should avoid consuming large amounts of fruit juices (especially orange, grapefruit, apple) within 1-2 hours of fexofenadine administration, as these inhibit OATP-mediated intestinal uptake and reduce efficacy by up to 60%.
Does not treat anaphylaxis:
Fexofenadine is not a substitute for epinephrine in anaphylactic reactions and should not be relied upon for acute severe allergic reactions.
Drug interactions
Fexofenadine has a favorable drug interaction profile compared to first-generation and some second-generation antihistamines due to lack of CYP450 metabolism. However, transporter-mediated interactions are clinically significant.
Pharmacokinetic interactions (reduced fexofenadine levels):
- Fruit juices: Orange, grapefruit, and apple juice inhibit OATP1A2 intestinal transporters, reducing fexofenadine absorption by 40-70%. Separate administration by at least 2 hours.
- Antacids (aluminum/magnesium hydroxide): Reduce fexofenadine AUC by ~40% when administered within 15 minutes. Space dosing by at least 2 hours.
- Rifampin: Induces P-glycoprotein, reducing fexofenadine levels by ~30%
- St. John's wort: May reduce fexofenadine exposure via P-glycoprotein induction
Pharmacokinetic interactions (increased fexofenadine levels):
- Ketoconazole and erythromycin: Inhibit P-glycoprotein, increasing fexofenadine AUC by 2-3 fold. Clinical significance is minimal since fexofenadine does not cause QT prolongation even at elevated levels.
- Verapamil: Increases fexofenadine bioavailability via P-glycoprotein inhibition
- Ritonavir and other potent P-gp inhibitors: May increase fexofenadine levels
Pharmacodynamic interactions:
- CNS depressants (benzodiazepines, opioids, alcohol): Additive sedation possible, though fexofenadine alone causes minimal sedation
- Anticholinergic drugs: Theoretical additive anticholinergic effects, though fexofenadine has minimal anticholinergic activity
No significant interactions:
Fexofenadine does not interact with:
- CYP450 substrates, inducers, or inhibitors
- Warfarin
- Theophylline
- Azithromycin
- Cimetidine (unlike other antihistamines)
The absence of CYP450-mediated interactions makes fexofenadine particularly suitable for patients on complex medication regimens.
Clinical pearls
High-yield exam concepts:
- Fexofenadine is the active carboxylic acid metabolite of terfenadine, created after terfenadine was withdrawn due to fatal arrhythmias. This metabolite lacks cardiotoxicity.
- No QT prolongation: The critical advantage over terfenadine. Fexofenadine does not block hERG potassium channels.
- Not metabolized by CYP450: Makes it immune to CYP3A4 inhibitor interactions that caused terfenadine's cardiac toxicity (ketoconazole, erythromycin, grapefruit juice no longer pose cardiac risk).
- Fruit juice interaction is unique: This is a transporter-mediated interaction (OATP inhibition), not a CYP450 interaction. Results in reduced efficacy, not toxicity.
Prescribing considerations:
- Timing: Can be dosed once or twice daily depending on formulation and indication
- Renal dosing: Reduce dose in CrCl <80 mL/min (important for exam questions involving elderly or renally impaired patients)
- Pregnancy: Second-generation antihistamines including fexofenadine are preferred over first-generation agents due to better safety profile and lack of sedation
- Comparative efficacy: Fexofenadine, cetirizine, and loratadine show similar efficacy for allergic rhinitis; choice often based on side effect profile (fexofenadine least sedating)
Patient counseling points:
- Take on an empty stomach or avoid fruit juice within 2 hours
- Separate from antacids by 2 hours
- Safe for activities requiring alertness (driving, operating machinery)
- May take 1-2 hours for symptom relief; works best when taken regularly during allergy season
- Not for acute severe allergic reactions
Exam traps:
- Question stem mentions fruit juice: Think reduced absorption and therapeutic failure
- History of terfenadine allergy: Fexofenadine is contraindicated (though it's the metabolite)
- Patient on ketoconazole: With terfenadine → torsades risk; with fexofenadine → no cardiac risk
- Renal failure scenario: Fexofenadine requires dose adjustment (renally cleared unchanged)
Comparison with other second-generation antihistamines:
| Feature | Fexofenadine | Cetirizine | Loratadine |
|---|---|---|---|
| Sedation rate | 1-3% | 10-15% | 8-10% |
| QT prolongation | No | No | No |
| CYP450 metabolism | Minimal | Minimal | Extensive (CYP3A4) |
| Renal clearance | ~10% | 70% | <1% |
| Duration | 12-24h | 24h | 24h |
FEXofenadine = FEw eXtra problems: Few CNS effects (non-sedating), eXcreted unchanged (no CYP450 metabolism), no cardiac problems (no QT prolongation)
Practice questions
1. A 28-year-old woman with seasonal allergic rhinitis has been taking fexofenadine 180 mg daily for the past week without improvement in her sneezing and rhinorrhea. She mentions she takes the medication every morning with a large glass of grapefruit juice. Her vital signs are normal and physical examination shows clear nasal discharge and pale, boggy nasal turbinates. Which of the following best explains her persistent symptoms?
2. A 45-year-old man with chronic idiopathic urticaria is started on fexofenadine. He has a history of atrial fibrillation and takes amiodarone. His physician chose fexofenadine specifically because of concerns about a previous antihistamine that was withdrawn from the market due to cardiac arrhythmias. Which property of fexofenadine makes it safe in this patient?
3. A 68-year-old woman with perennial allergic rhinitis and stage 3 chronic kidney disease (estimated GFR 45 mL/min/1.73 m²) is prescribed fexofenadine. Which of the following pharmacokinetic properties of fexofenadine is most relevant when determining her dosing regimen?
Frequently asked questions
How does fexofenadine work?
Fexofenadine works by selectively blocking peripheral histamine H1 receptors, preventing histamine from binding and triggering allergic symptoms. Unlike first-generation antihistamines, it does not cross the blood-brain barrier due to its zwitterionic structure and active efflux by P-glycoprotein transporters, which explains its non-sedating properties. It competitively inhibits histamine effects on vascular endothelium and smooth muscle, reducing symptoms like sneezing, itching, rhinorrhea, and hives without causing drowsiness or anticholinergic side effects.
What are the side effects of fexofenadine?
Fexofenadine is very well-tolerated with side effects similar to placebo. The most common side effect is headache, occurring in 5-10% of patients. Mild drowsiness occurs in only 1-3% (much lower than first-generation antihistamines), along with occasional dizziness, nausea, or fatigue. Serious side effects are extremely rare but may include hypersensitivity reactions such as rash, urticaria, or very rarely anaphylaxis. Importantly, fexofenadine does not cause cardiac arrhythmias or QT prolongation, unlike its parent compound terfenadine.
Is fexofenadine a controlled substance?
No, fexofenadine is not a controlled substance and is not scheduled under the Controlled Substances Act. It is available over-the-counter in many countries without a prescription for adults and children meeting age requirements. Fexofenadine has no abuse potential, does not cause dependence, and lacks psychoactive effects because it does not penetrate the central nervous system. This makes it safe for regular long-term use in managing chronic allergic conditions without concerns about addiction or withdrawal.
Can I take fexofenadine with grapefruit juice?
No, you should avoid taking fexofenadine with grapefruit juice or other fruit juices like orange or apple juice. These juices inhibit organic anion transporting polypeptides (OATP) in the intestine, which are responsible for absorbing fexofenadine into the bloodstream. This interaction can reduce fexofenadine absorption by 40-70%, significantly decreasing its effectiveness in controlling allergy symptoms. To avoid this problem, take fexofenadine with water and separate it from fruit juice consumption by at least 2 hours before or after your dose.
Fexofenadine vs cetirizine—what is the difference?
Fexofenadine and cetirizine are both second-generation antihistamines used for allergies, but differ mainly in their sedation potential and metabolism. Fexofenadine causes sedation in only 1-3% of patients (similar to placebo), while cetirizine causes drowsiness in 10-15% due to some CNS penetration. Both are minimally metabolized and renally excreted, requiring dose adjustment in kidney disease. Neither causes cardiac side effects. Fexofenadine has clinically significant interactions with fruit juices and antacids, while cetirizine does not. Efficacy for allergic rhinitis and urticaria is comparable between the two drugs.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: R06AX26
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.